University of California San Francisco

Csaba J Peto, Ph.D.
Csaba
Peto
PhD

Associate Professor of Surgery
Division of Cardiothoracic Surgery
Thoracic Oncology Laboratory 

Address

2340 Sutter Street, #N215
San Francisco, CA 94115
United States

Email: [email protected]

Biography

Csaba J. Peto, Ph.D. joined the Thoracic Oncology Laboratory in January 2013 as a synthetic medicinal chemist. His primary research focus is the discovery and development of small molecule drug candidates for cancer therapy. Previous to his appointment as a specialist at UCSF, Dr. Peto has has twenty years of experience in the biotech industry, notably at Tualrik and Exelixis.  

Education

Education

University of Debrecen, Hungary, B.S., Biology & Chemistry, 1989

University of Debrecen, Hungary Ph.D., Organic Chemistry, 1997

Research Narrative

Dr. Peto designs and synthesizes compounds for multi parametric optimization. During his tenure at Exelixis, Inc., Dr. Peto played a key role in research and development of orally available, small molecule kinase inhibitors that target oncogenic signaling pathways, identifying five development candidates (IND), of which four entered into clinical trials, most notably GDC-0973, a small molecule MEK inhibitor.

Research Interests

Small molecule kinase inhibitors

Carbohydrate based therapeutics.

Research Pathways

Basic Biomedical & Translational Research

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 5
  1. Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy.
    Brand NR, Yang YW, Ding V, Dutta H, Peto CJ, Lemjabbar-Alaoui H, Jablons DM| | View in PubMed
  2. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
    Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM| | View in PubMed
  3. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
    Liu S, Hsieh D, Yang YL, Xu Z, Peto C, Jablons DM, You L| | View in PubMed
  4. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
    Bussenius J, Blazey CM, Aay N, Anand NK, Arcalas A, Baik T, Bowles OJ, Buhr CA, Costanzo S, Curtis JK, DeFina SC, Dubenko L, Heuer TS, Huang P, Jaeger C, Joshi A, Kennedy AR, Kim AI, Lara K, Lee J, Li J, Lougheed JC, Ma S, Malek S, Manalo JC, Martini JF, McGrath G, Nicoll M, Nuss JM, Pack M, Peto CJ, Tsang TH, Wang L, Womble SW, Yakes M, Zhang W, Rice KD| | View in PubMed
  5. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).
    Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S| | View in PubMed